SAN DIEGO, April 29 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel compounds for the treatment of central nervous system (CNS) diseases, announced today that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,678,808 entitled, "5 HT Receptor Mediated Neurogenesis." The patent gives BrainCells coverage for treating depression with buspirone, a 5HTR agent, in combination with melatonin, by way of stimulating the formation of new nerve cells, or neurogenesis. Buspirone and melatonin are the two active agents in BCI-952, a compound that was selected by BrainCells' platform and that demonstrated proof-of-concept in a clinical study.
